GROUP
AMOREPACIFIC GROUP 202014 Earnings Release

1 1H2014Earnings Summary
2 202014Earnings Summary
3 Earnings by Subsidiary
4 Financial Summary

As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.

AMOREPACIFIC GROUP has adopted the K-IFRS since 2011.

Sales up 15.6\% to KRW 2,316.5bn, OP up 32.0\% to KRW386.2bn

Sales \& OP by Division

|  | 1H 2013 | \% of sales | 1 H 2014 | \% of sales | YoY(\%) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Sales | $2,004.3$ | 100.0 | $2,316.5$ | 100.0 | 15.6 |
| Cosmetics1) | $1,865.9$ | 93.1 | $2,189.3$ | 94.5 | 17.3 |
| Non-cosmetics2) | 138.4 | 6.9 | 127.2 | 5.5 | -8.1 |
| Operating Profit | 292.6 | OPM | 1 H 2014 | OPM | YoY(\%) |
| Cosmetics | 287.2 | 14.6 | 386.2 | 16.7 | 32.0 |
| Non-cosmetics | 5.4 | 15.4 | 386.3 | 17.6 | 34.5 |
| Net Profit | 215.9 | 3.9 | 10.8 | 319.4 | 0.0 |

1) Cosmetics: AMOREPACIFIC, Etude, Innisfree, Amos Professional, Adjustment
2) Non-cosmetics: AMOREPACIFIC Group, Pacific Pharma., Pacific Glas, Pacific Package, Jangwon Industry
$\mathbf{I R}_{2004}^{20} \mid 202014$ Earnings summary

## Sales up 14.9\% to KRW 1,176.8bn,OP up 44.9\% to KRW 1723bn

Sales \& OP by Division

|  | 20.2013 | \% of sales | 20.2014 | \% of sales | YoY(\%) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Sales | $1,024.1$ | 100.0 | $1,176.8$ | 100.0 | 14.9 |
| Cosmetics1) | 950.9 | 92.9 | $1,106.8$ | 94.1 | 16.4 |
| Non-cosmetics2) | 73.2 | 7.1 | 70.0 | 5.9 | -4.4 |
| Operating Profot | 118.9 | OPM | 20.2014 | OPM | YoY(\%) |
| Cosmetics | 115.0 | 11.6 | 172.3 | 14.6 | 44.9 |
| Non-cosmetics | 4.0 | 12.1 | 172.4 | 15.6 | 50.0 |
| Net Profit | 98.9 | 5.4 | $10.1)$ | $10.2)$ | -102.8 |

1) Cosmetics: AMOREPACIFIC, Etude, Innisfree, Amos Professional, Adjustment
2) Non-cosmetics: AMOREPACIFIC Group, Pacific Pharma., Pacific Glas, Pacific Package, Jangwon Industry
$\mathbf{I R}_{2044}^{204} \mid$ Earnings by Subsidiary(1/3)


## AMOREPACIFIC: Sales + $21 \%$, OP +69\%

Domestic Cosmetics
-(Luxury) Continued strong growth within travel retail channel behind by increased sales to foreign travelers, Achieved market share no. 1 position within Dep. store channel backed by a differentiated brand portfolio
-(Premium) Strengthened competitiveness of store formats and services resulted in solid growth of specialty store channel, Robust growth of digital channel on the back of a differentiated product portfolio

Mass \& Sulloc
-(Mass) Slightly decreased sales due to competitive environment and slowing market, Continued premiumization through strong sales from cosmetics category
-(Sulloc) Enhanced brand recognition of OSULLOC, Expanded sales contribution of premium business
Overseas business
-(Growth markets) Enhanced brand power and diversified distribution channel led to continued strong profitable growth
-(Developed markets) Profitable growth in US delivered by increased sales of hit products and diversified distribution portfolio, Decreased sales in France and Japan due to slowdown of European market and the effect of consumption tax hike in Japan

## Innisfree: Sales +38\%, OP +63\%

- Solid growth throughout all channels in domestic market delivered by increased sales of major products (Green tea, Jeju volcanic, Cedar wood lines)
- Increased export sales on the back of accelerated expansion of overseas business, Strong growth of travel retail channel behind by increased no. of foreign travelers
- Improved profitability across all channels delivered by reduced discount policy


## Etude: Sales -12\%, OP -116\%

- Decreased sales across all channels due to reduced discount policy in domestic market, Decreased export sales due to cuts in transaction with overseas agents
- Decreased OP due to decreased sales and increased investments in marketing activities to strengthen brand power

|  | AMOREPACIFIC _ Consolidated |  |
| :---: | :---: | :---: |
|  | 201320 | 201420 |
| Sales | 799.0 | 966.7 |
| GP | 569.0 | 715.9 |
| SG\&A expenses | 479.4 | 564.8 |
| OP | 89.5 | 151.1 |
|  | Innisfree |  |
| Sales | 83.9 | 115.8 |
| GP | 57.9 | 81.3 |
| SG\&A expenses | 45.7 | 61.4 |
| OP | 12.2 | 19.9 |
|  | Etude |  |
| Sales | 86.2 | 75.5 |
| GP | 47.5 | 43.7 |
| SG\&A expenses | 40.4 | 44.9 |
| OP | 7.1 | (1.2) |

KRW bn

## $\mathbf{I R}_{2044}^{20} \mid$ Earnings by Subsidiary(3/3)

## Amos Professional: Sales +7\%, OP -5\%

- Increased sales of major products from hair tonic, colorants and cleansing categories and strong growth of travel retail channel led to solid growth
- Weakened profitability due to increased commission caused by increased sales contribution of travel retail channel


## Pacific Pharma.: Sales -23\%, OP -81\%

- Decreased sales and OP resulted from the transfer of pharmaceutical business
- Decreased profits due to the increased marketing investment to strengthen its capacities as a Medical Beauty company


## Pacific Glas: Sales +11\%, OP -54\%

- Decent growth delivered by increased sales to affiliates and non-affiliates
- Slightly increased COGS ratio caused by expanded product facility, Decreased profits due to consulting fees for renovation of production process

|  | Amos Professional |  |
| :---: | :---: | :---: |
|  | 201320 | 201420 |
| Sales | 12.3 | 13.2 |
| GP | 6.7 | 7.1 |
| SG\&A expenses | 3.5 | 4.0 |
| OP | 3.2 | 3.1 |
|  | Pacific Pharma. |  |
| Sales | 36.6 | 28.1 |
| GP | 14.0 | 6.2 |
| SG\&A expenses | 11.4 | 5.7 |
| OP | 2.6 | 0.5 |
|  | Pacific Glas |  |
| Sales | 14.5 | 16.1 |
| GP | 1.4 | 1.6 |
| SG\&A expenses | 1.3 | 1.5 |
| OP | 0.1 | 0 |

KRW bn

## Income Statement

KRW bn

|  | 20.2013 |  | 202014 |  |
| :---: | :---: | :---: | :---: | :---: |
| Sales | $1,024.1$ | $100.0 \%$ | $1,176.8$ | $100.0 \%$ |
| Gross profit | 700.0 | $68.3 \%$ | 853.4 | $72.5 \%$ |
| SG\&A expenses | 581.1 | $56.7 \%$ | 681.1 | $57.9 \%$ |
| Operating profit | 118.9 | $11.6 \%$ | 172.3 | $14.6 \%$ |
| Non-operating <br> profit/expenses | 11.8 |  | $12.0)$ |  |
| Profit before tax | 130.7 | $12.8 \%$ | 170.3 | $14.5 \%$ |
| Consolidated net income | 98.9 | $9.7 \%$ | 128.6 | $10.9 \%$ |

Statements of Financial Position

|  | 2013.12 | 2014.06 |
| :---: | :---: | :---: |
| Assets | 4,921.9 | 5,207.6 |
| Current assets | 1,552.3 | 1,776.3 |
| Non-current assets | 3,369.6 | 3,431.3 |
| Liabilities | 1,012.9 | 1,053.6 |
| Current liabilities | 644.3 | 678.4 |
| Non-current liabilities | 368.6 | 375.2 |
| Shareholder's Equity | 3,908.9 | 4,154.0 |
| Capital stock | 44.5 | 44.5 |
| Additional paid-in capital | 673.0 | 673.0 |
| Capital surplus | 22.6 | 22.6 |
| Other components of equity | (140.8) | (143.8) |
| Accumulated other comprehensive income | (7.3) | (11.0) |
| Retained earnings | 1,533.7 | 1,663.5 |
| Non-controlling interest | 1,783.3 | 1,905.2 |

